OncoGenex Pharma (OGXI) Tops Q4 EPS by 4c

OncoGenex Pharma (NASDAQ: OGXI) reported Q4 EPS of ($0.26), $0.04 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $5.7 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on OncoGenex Pharma (OGXI) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor